Scholar Rock
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
301 Binney St Ste 3, Cambridge, Massachu...Phone Number
(857) 259-3860Website
www.scholarrock.comRevenue
-Stock Symbol
SRRKIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
4
1
1
1
1
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company specializing in the discovery and development of medicines and the treatment of serious diseasesExplore more
Scholar Rock Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Scholar Rock your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Scholar Rock has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Scholar Rock, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Scholar Rock launches new products
Click to see if Scholar Rock had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Scholar Rock has new funding data
Earning: See what the market has to say on Scholar Rock recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Scholar Rock
Check out if Scholar Rock is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Scholar Rock as Masked Content
Find more new buyers
Compare Similar Companies to Scholar Rock
Compare insights from companies similar to Scholar Rock, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Scholar Rock is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Scholar Rock is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Scholar Rock.
Scholar Rock financials insights
Gather financial insights about Scholar Rock, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$20M
2016
Series B
$36M
2018
Series C
$47M
Stock Offering
$86.3M
2019
Stock Offering
$51.8M
2020
Debt
$50M
Stock Offering
$230M
2022
Stock Offering
$205M
Scholar Rock Tech Stack
A closer look at the technologies used by Scholar Rock
Most Recent Scoops
Open Position
Open Position
Earnings
reported $102 million in operating expenses for Q1, which included $80 million in non-cash stock-based compensation; excluding stock-based compensation, operating expenses were $84 million.
Earnings, Finance
Project
Scholar Rock announced that the EMA review of its Marketing Authorization Application (MAA) for apitegromab for the treatment of children and adults with SMA is progressing well, with a previously planned oral explanation meeting mutually waived after alignment was reached with the EMA ahead of the scheduled meeting.
Pharmaceuticals
Earnings
Earnings, Finance, Financing & Debt
Scholar Rock News & Media
Scholar Rock Q1 Earnings Call Highlights
Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for children and adults with spinal muscular atrophy, and set a PDUFA action date of Sept. 30, 2026. CScholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call May 7, 2026 8:00 AM EDTCompany ParticipantsLaura EkasDavid Hallal - CEO & Chairman of the...Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept.
Scholar Rock (NASDAQ:SRRK) said it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for apitegromab as a treatment for children and adults with spinal muscular atrophy (SMA), positioning the company for a new review cycle and a potential regulatory decScholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript
Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress March 31, 2026 8:00 AM...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Scholar Rock
Sign Up For FreeTo access detailed company insights
Scholar Rock is a clinical-stage biopharmaceutical company specializing in the discovery and development of medicines and the treatment of serious diseases... Read More
